vs

Side-by-side financial comparison of MongoDB, Inc. (MDB) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

MongoDB, Inc. is the larger business by last-quarter revenue ($628.3M vs $622.0M, roughly 1.0× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs -0.3%, a 34.8% gap on every dollar of revenue. On growth, MongoDB, Inc. posted the faster year-over-year revenue change (18.7% vs 4.8%). Over the past eight quarters, MongoDB, Inc.'s revenue compounded faster (17.1% CAGR vs 4.6%).

MongoDB, Inc. is an American software company that develops and provides commercial support for the source-available database engine MongoDB, a database for unstructured data. Over the years, the company has expanded the product from its NoSQL roots to have broader appeal to enterprise customers, such as adding ACID and transactions.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

MDB vs RPRX — Head-to-Head

Bigger by revenue
MDB
MDB
1.0× larger
MDB
$628.3M
$622.0M
RPRX
Growing faster (revenue YoY)
MDB
MDB
+13.9% gap
MDB
18.7%
4.8%
RPRX
Higher net margin
RPRX
RPRX
34.8% more per $
RPRX
34.4%
-0.3%
MDB
Faster 2-yr revenue CAGR
MDB
MDB
Annualised
MDB
17.1%
4.6%
RPRX

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
MDB
MDB
RPRX
RPRX
Revenue
$628.3M
$622.0M
Net Profit
$-2.0M
$214.2M
Gross Margin
71.5%
Operating Margin
-2.9%
62.4%
Net Margin
-0.3%
34.4%
Revenue YoY
18.7%
4.8%
Net Profit YoY
79.5%
2.9%
EPS (diluted)
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDB
MDB
RPRX
RPRX
Q4 25
$628.3M
$622.0M
Q3 25
$591.4M
$609.3M
Q2 25
$549.0M
$578.7M
Q1 25
$548.4M
$568.2M
Q4 24
$529.4M
$593.6M
Q3 24
$478.1M
$564.7M
Q2 24
$450.6M
$537.3M
Q1 24
$458.0M
$568.0M
Net Profit
MDB
MDB
RPRX
RPRX
Q4 25
$-2.0M
$214.2M
Q3 25
$-47.0M
$288.2M
Q2 25
$-37.6M
$30.2M
Q1 25
$15.8M
$238.3M
Q4 24
$-9.8M
$208.2M
Q3 24
$-54.5M
$544.0M
Q2 24
$-80.6M
$102.0M
Q1 24
$-55.5M
$4.8M
Gross Margin
MDB
MDB
RPRX
RPRX
Q4 25
71.5%
Q3 25
71.0%
Q2 25
71.2%
Q1 25
72.8%
Q4 24
74.4%
Q3 24
73.2%
Q2 24
72.8%
Q1 24
75.0%
Operating Margin
MDB
MDB
RPRX
RPRX
Q4 25
-2.9%
62.4%
Q3 25
-11.0%
70.1%
Q2 25
-9.8%
36.3%
Q1 25
-3.4%
94.0%
Q4 24
-5.3%
60.9%
Q3 24
-14.9%
Q2 24
-21.8%
50.2%
Q1 24
-15.5%
-13.0%
Net Margin
MDB
MDB
RPRX
RPRX
Q4 25
-0.3%
34.4%
Q3 25
-8.0%
47.3%
Q2 25
-6.9%
5.2%
Q1 25
2.9%
41.9%
Q4 24
-1.8%
35.1%
Q3 24
-11.4%
96.3%
Q2 24
-17.9%
19.0%
Q1 24
-12.1%
0.8%
EPS (diluted)
MDB
MDB
RPRX
RPRX
Q4 25
$0.49
Q3 25
$0.67
Q2 25
$0.07
Q1 25
$0.55
Q4 24
$0.46
Q3 24
$1.21
Q2 24
$0.23
Q1 24
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDB
MDB
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$834.1M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$2.9B
$9.7B
Total Assets
$3.6B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDB
MDB
RPRX
RPRX
Q4 25
$834.1M
$618.7M
Q3 25
$647.1M
$938.9M
Q2 25
$657.8M
$631.9M
Q1 25
$490.1M
$1.1B
Q4 24
$673.1M
$929.0M
Q3 24
$1.3B
$950.1M
Q2 24
$815.7M
$1.8B
Q1 24
$803.0M
$843.0M
Total Debt
MDB
MDB
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
MDB
MDB
RPRX
RPRX
Q4 25
$2.9B
$9.7B
Q3 25
$2.9B
$9.6B
Q2 25
$3.0B
$9.5B
Q1 25
$2.8B
$9.8B
Q4 24
$1.5B
$10.3B
Q3 24
$1.4B
$10.3B
Q2 24
$1.3B
$9.8B
Q1 24
$1.1B
$9.9B
Total Assets
MDB
MDB
RPRX
RPRX
Q4 25
$3.6B
$19.6B
Q3 25
$3.5B
$19.3B
Q2 25
$3.6B
$18.3B
Q1 25
$3.4B
$17.6B
Q4 24
$3.2B
$18.2B
Q3 24
$3.1B
$18.0B
Q2 24
$3.0B
$17.7B
Q1 24
$2.9B
$16.1B
Debt / Equity
MDB
MDB
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDB
MDB
RPRX
RPRX
Operating Cash FlowLast quarter
$143.5M
$827.1M
Free Cash FlowOCF − Capex
$141.8M
FCF MarginFCF / Revenue
22.6%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters
$346.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDB
MDB
RPRX
RPRX
Q4 25
$143.5M
$827.1M
Q3 25
$72.1M
$702.6M
Q2 25
$109.9M
$364.0M
Q1 25
$50.5M
$596.1M
Q4 24
$37.4M
$742.5M
Q3 24
$-1.4M
$703.6M
Q2 24
$63.6M
$658.2M
Q1 24
$54.6M
$664.6M
Free Cash Flow
MDB
MDB
RPRX
RPRX
Q4 25
$141.8M
Q3 25
$71.6M
Q2 25
$108.3M
Q1 25
$24.6M
Q4 24
$35.5M
Q3 24
$-2.4M
Q2 24
$63.1M
Q1 24
$51.9M
FCF Margin
MDB
MDB
RPRX
RPRX
Q4 25
22.6%
Q3 25
12.1%
Q2 25
19.7%
Q1 25
4.5%
Q4 24
6.7%
Q3 24
-0.5%
Q2 24
14.0%
Q1 24
11.3%
Capex Intensity
MDB
MDB
RPRX
RPRX
Q4 25
0.3%
Q3 25
0.1%
Q2 25
0.3%
Q1 25
4.7%
Q4 24
0.4%
Q3 24
0.2%
Q2 24
0.1%
Q1 24
0.6%
Cash Conversion
MDB
MDB
RPRX
RPRX
Q4 25
3.86×
Q3 25
2.44×
Q2 25
12.06×
Q1 25
3.19×
2.50×
Q4 24
3.57×
Q3 24
1.29×
Q2 24
6.45×
Q1 24
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDB
MDB

Mongo DB Atlas Related$470.4M75%
Other Subscription$138.7M22%
Services$19.2M3%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons